SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biochem Pharma (BCHE)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Oravetz who wrote (666)10/21/1999 12:28:00 PM
From: Jim Oravetz  Read Replies (1) of 783
 
Biochem Pharma/Drug Devt -2: dOTC Has FDA Fast-Track Ok

LAVAL, Quebec -- BioChem Pharma Inc. (BCHE) expects to have nine drugs or vaccines in its development pipeline by year's end.

In a press release Tuesday, the biopharmaceutical company also said it expects to have 12 drugs and vaccines in varying stages of clinical development by the end of next year.

BioChem completed a Phase I/II trial of its anti-HIV drug called dOTC in HIV-infected animal subjects and observed toxicity in some animals.

The company said it is believed the toxicity is species-specific, but added that the company will delay the start of Phase II/III trials in humans until the species theory can be confirmed.

dOTC was granted fast-track status by the Food & Drug Administration, BioChem said.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News